Iovance Biotherapeutics Inc
Business Description
Iovance Biotherapeutics Inc. is a biotechnology company that specializes in developing novel cancer immunotherapies. The company is headquartered in San Carlos, California, and was founded in 200
The primary focus of Iovance Biotherapeutics is to harness the power of a patient*s own immune system to target and eliminate cancer cells. The company*s innovative approach involves isolating white blood cells called tumor-infiltrating lymphocytes (TILs) from a patient*s tumor tissue and expanding them in the lab to create a personalized treatment.
Iovance*s lead product candidate is LN-144, also known as lifileucel, which is being developed for the treatment of metastatic melanoma and other solid tumors. LN-144 is created by enriching TILs from the patient*s tumor and expanding them in the lab to increase their number. These activated TILs are then infused back into the patient to recognize and kill cancer cells.
The company*s second product candidate is called LN-145, also known as lifileucel, which is being developed for the treatment of cervical cancer. LN-145 follows a similar approach as LN-144, where TILs are extracted from the patient*s tumor and expanded in the lab to create a personalized therapy.
Iovance Biotherapeutics has also developed a proprietary technology platform called Tumor-Infiltrating Lymphocyte Therapy0 (TIL Therapy0), which helps in the efficient expansion of TILs for large-scale commercial production.
In addition to its clinical pipeline, Iovance Biotherapeutics is actively involved in research and development efforts to explore the potential of TIL therapy in other cancer indications. The company seeks to address the significant unmet need in cancer treatment through its cutting-edge immunotherapies.
Iovance Biotherapeutics collaborates with renowned academic institutions, cancer centers, and pharmaceutical companies to further advance its research and development initiatives. The company has established strategic partnerships with organizations like The National Cancer Institute, Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, and Merck.
As a publicly traded company, Iovance Biotherapeutics is listed on Nasdaq under the ticker symbol IOVA. The company has a team of experienced scientists, researchers, and industry professionals who are dedicated to advancing the field of immuno-oncology and revolutionizing cancer treatment.
Overall, Iovance Biotherapeutics Inc. is at the forefront of developing personalized cancer immunotherapies using TILs and has the potential to significantly impact the future of cancer treatment.
|